Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 19, 2019
Reporting Period: Single event date (June 19, 2019)
Business Context: The Company is an emerging growth company incorporated in Nevada, trading on NASDAQ under the symbol IMNB. This filing serves as a Regulation FD disclosure regarding the publication of an Investor Fact Sheet on the Company's website.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate communication (Investor Fact Sheet) rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The material event is the release of updated information regarding the Company's product pipeline, clinical trials, and leadership.
Guidance, Outlook, and Risks
- Management Commentary: The Company published a Fact Sheet containing updates on its product pipeline and clinical trials, as well as leadership information.
- Exhibit Status: The Fact Sheet is furnished as Exhibit 99.1. It is explicitly stated that this exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to liabilities under that Section.
- Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K filing.
Investor Verification Checklist
- Verify the content of the Investor Fact Sheet (Exhibit 99.1) for specific details on pipeline updates and clinical trial status, as the 8-K body only references its existence.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the Fact Sheet is not legally "filed" under Section 18 of the Exchange Act, which may impact liability considerations for the information contained therein.